

**Claims:**

1. An immunogenic fragment of a Cripto polypeptide wherein the immunogenic fragment is immunologically reactive with an antibody and/or T-cell that reacts with a polypeptide of SEQ ID NO:3 or SEQ ID NO:4, wherein said immunogenic  
5 fragment is at least 20 contiguous amino acids in length, comprises SEQ ID NO:97 and does not contain SEQ ID NO:11 and SEQ ID NO:12.
2. The immunogenic fragment of claim 1, wherein the fragment is part of a fusion protein.
3. The immunogenic fragment of claim 1, wherein the fragment is chemically  
10 conjugated to a carrier protein.
4. An isolated polynucleotide encoding an immunogenic fragment of claim 1.
5. An expression vector comprising an isolated polynucleotide of claim 4 operably linked to an expression control sequence.
6. A recombinant viral or bacterial delivery system comprising an isolated  
15 polynucleotide of claim 4.
7. A host cell comprising the isolated polynucleotide of claim 4.
8. An immunogenic composition comprising a first component comprising a physiologically acceptable carrier, immunostimulant, and adjuvant, and a second component comprising an immunogenic fragment of claim 1.
- 20 9. The immunogenic composition of claim 8, wherein the immunostimulant is a TH-1 inducing adjuvant.
10. The immunogenic composition of claim 9, wherein the TH-1 inducing adjuvant comprises 3D-MPL, QS21, a mixture of QS21 and cholesterol, and a CpG oligonucleotide.
- 25 11. A method for the treatment of cancer in a patient, comprising administering to the patient an immunogenic composition according to claim 8.
12. A method for stimulating T cells specific for Cripto, comprising contacting said cells with an immunogenic fragment of a Cripto polypeptide wherein the immunogenic fragment is immunologically reactive with an antibody and/or T-cell

that reacts with a full-length polypeptide of SEQ ID NO:3 or SEQ ID NO:4, wherein said immunogenic fragment is at least 20 contiguous amino acids in length, comprises SEQ ID NO:97 and does not contain SEQ ID NO:11 or SEQ ID NO:12.

5 13. An isolated T cell population comprising T cells prepared according to the method of claim 12.

14. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

(c) incubating CD4+ and/or CD8+ T cells isolated from a patient with SEQ ID NO:97; and

10 (d) administering to the patient an effective amount of the T cells, and thereby inhibiting the development of a cancer in the patient.

15. The method of claim 14, further comprising the step of allowing the T cells to proliferate.

15 16. A method for producing an immunogenic response to Cripto in an animal comprising administering a first component comprising a polynucleotide encoding SEQ ID NO:97 and does not encode SEQ ID NO:3 or SEQ ID NO:4 to the animal.

17. The method of claim 16, wherein the polynucleotide is recombinant DNA.

20 18. The method of claim 16, further comprising admixing the polynucleotide with a second component comprising an immunostimulant, adjuvant and physiologically acceptable carrier.

19. A method of inducing an immunoresponse to Cripto in an animal comprising repeatedly administering a composition comprising a first component comprising SEQ ID NO:97.

25 20. The method of claim 19 further comprising admixing the first component and a second component comprising a physiologically acceptable carrier, adjuvant and immunostimulant prior to administering the first component to the animal.